• Weinheimer-Haus EM, Yu X, Singal AG, Naylor KB, Ammori C, Coyle J, Nallamothu BK, Witala W, Zhu J, Waljee AK. Utilizing public health data to geotarget hepatitis C virus elimination approaches in urban and rural Michigan. Journal of Viral Hepatitis. 2021 Feb 1; 28(2):440-444.
• Chen Q, Ayer T, Adee MG, Wang X, Kanwal F, Chhatwal J. Assessment of Incidence of and Surveillance Burden for Hepatocellular Carcinoma Among Patients With Hepatitis C in the Era of Direct-Acting Antiviral Agents. JAMA Network Open. 2020 Nov 2; 3(11):e2021173.
• Ismail MS, Hassan M, Khaderi SA, Yousry WA, Kamal El-Din MM, Bahaa El-Din MM, El Sayed OA, Kaseb AO, Goss JA, Kanwal F, Jalal PK. Clinical efficacy of direct-acting antiviral therapy for recurrent hepatitis C virus infection after liver transplantation in patients with hepatocellular carcinoma. World journal of hepatology. 2020 Sep 27; 12(9):628-640.
• Vutien P, Kim NJ, Moon AM, Pearson M, Su F, Berry K, Gelman H, Ioannou GN. Fibroscan liver stiffness after anti-viral treatment for hepatitis C is independently associated with adverse outcomes. Alimentary pharmacology & therapeutics. 2020 Dec 1; 52(11-12):1717-1727.
• Yakovchenko V, DeSotto K, Drainoni ML, Lukesh W, Miller DR, Park A, Shao Q, Thornton DJ, Gifford AL. Using Lean-Facilitation to Improve Quality of Hepatitis C Testing in Primary Care. Journal of general internal medicine. 2020 Sep 15.

» View more Citations

• Veterans Advocate Treating “Sickest First” When Discussing Limited Resources for Hepatitis C Treatment
  Investigators in this study used Democratic Deliberation (DD) methods as a proof of concept for informing policy decisions related to the allocation of scarce resources for treatment of chronic hepatitis C virus in VA. Findings showed that most Veterans endorsed a sickest-first policy over a first-come-first-served policy, emphasizing the ethical and medical appropriateness of treating the sickest...
  
  Date: May 1, 2020
• VA Successfully Implements Interferon-free Treatment for Hepatitis C Virus in Previously Undertreated Patient Populations
  This study examined the adoption of interferon-free treatment for hepatitis C virus (HCV) in VA to learn who received this therapy and whether the limitations of interferon-containing treatments have been overcome, including low rates of use among VA healthcare users who are African American or Hispanic, and among those with HCV-HIV co-infection. Findings showed that with the advent of interferon-...
  
  Date: March 7, 2018
• HCV-Related Complications Increasing among Women Veterans
  This study examined gender-related differences in the incidence and prevalence of cirrhosis, decompensated cirrhosis, and hepatocellular cancer (HCC) between 2000 and 2013. Findings showed that the incidence and prevalence of hepatitis C virus (HCV) complications was higher in men than in women. However, the rate of increase in the incidence rates of cirrhosis and decompensated cirrhosis among HCV...
  
  Date: November 1, 2017
• Direct-Acting Antiviral Agents Reduce Risk of Hepatocellular Cancer among Veterans with Hepatitis C
  This study examined the risk of hepatocellular cancer (HCC) following sustained virological response (SVR) among 22,500 Veterans with hepatitis C virus (HCV) who received directing-acting antivirals (DAA) treatment at any of 129 VA hospitals between January and December 2015. Findings showed that in Veterans treated with DAAs, SVR was associated with a 76% reduction in the risk of developing hepat...
  
  Date: October 1, 2017
• VA Hepatitis C Care and Experiences with the Choice Program
  This study examined perspectives and experiences with the VA Choice Program among Veterans with HCV and their providers at three VAMCs in the New England region. Findings showed that the Choice Program has the potential to increase Veterans’ access to hepatitis C virus (HCV) treatment, but Veterans and VA providers described substantial problems in the initial years of the program. Four main theme...
  
  Date: March 3, 2017

» View more Publication Briefs

» View more Studies

• Management Briefs eBrief-no67 -- Assessment of Alternative Treatment Strategies for Chronic Genotype 1 Hepatitis C

  Strategies for Chronic Genotype 1 Hepatitis C...Genotype 1 Hepatitis C: A Systematic Review Chronic genotype 1 (GT1) Hepatitis C (HCV)...Strategies for Chronic Genotype 1 Hepatitis C. VA ESP Project #05-226, 2012. View

• Assessment of Alternative Treatment Strategies for Chronic Genotype 1 Hepatitis C

  Strategies for Chronic Genotype 1 Hepatitis C Subscribe to the ESP Report RSS...patients with chronic genotype 1 (GT1) Hepatitis C (HCV) infections through the use

• FORUM, Spring 2017: Implementation Science

  Increase Hepatitis C Treatment Starts Rachel Gonzalez, MPH, National Hepatitis C Resource...System, Pittsburgh, Pennsylvania Hepatitis C virus (HCV) infection is a leading

• Veterans' Views on Limited Resources: Help Sickest First

  ...limited resources in combating chronic hepatitis C, which may offer insights into how...antiviral treatment for chronic hepatitis C virus (CHC) infection. Without treatment

• FORUM, Spring 2017: Implementation Science

  ...record data... Strategies to Increase Hepatitis C Treatment Starts By Rachel Gonzalez...Gonzalez, MPH, National Hepatitis C Resource Center, VA Long Beach Healthcare System

» View more Publications

» View more Cyberseminars

Videos

There are currently no videos for this topic.

Podcasts

There are currently no podcasts for this topic.

Other Resources

• Visit the VA’s health information page for Veterans on hepatitis C.
• Learn more about the relationship between substance use disorders and hepatitis C through the “Promoting Value & Access in VA's Substance Use Disorder Services” CREATE
• Learn more about the Quality Enhancement Research Initiative’s Bridging the Care Continuum project focusing on liver disease outreach.